[
  {
    "ts": null,
    "headline": "Biogen (BIIB) Stock Trades Down, Here Is Why",
    "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a \"Hold\" rating on the stock. This rating suggests the analyst expects the stock to perform in line with the broader market, lacking a significant catalyst for a major move in either direction. The reiterated neutral stance comes with no change to the price target. The market's negative reaction may indicate that some investors were anticipating a more positive outlook or an",
    "url": "https://finnhub.io/api/news?id=e4018b65febe0fd98181b8c06144f112450136f2dd9e7e406b84afd24cf758a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757014589,
      "headline": "Biogen (BIIB) Stock Trades Down, Here Is Why",
      "id": 136642857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a \"Hold\" rating on the stock. This rating suggests the analyst expects the stock to perform in line with the broader market, lacking a significant catalyst for a major move in either direction. The reiterated neutral stance comes with no change to the price target. The market's negative reaction may indicate that some investors were anticipating a more positive outlook or an",
      "url": "https://finnhub.io/api/news?id=e4018b65febe0fd98181b8c06144f112450136f2dd9e7e406b84afd24cf758a7"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
    "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757007155,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
      "id": 136639750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
      "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3"
    }
  },
  {
    "ts": null,
    "headline": "C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration",
    "summary": "Development Candidate Targeting IRAK4 Now Progressing Toward Clinical DevelopmentWATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to",
    "url": "https://finnhub.io/api/news?id=c612a80aa45d7b0fc1b6c79ce2ccd4a380a4c6028b7814d53a8af1b32b43d3d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756987200,
      "headline": "C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration",
      "id": 136642859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Development Candidate Targeting IRAK4 Now Progressing Toward Clinical DevelopmentWATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to",
      "url": "https://finnhub.io/api/news?id=c612a80aa45d7b0fc1b6c79ce2ccd4a380a4c6028b7814d53a8af1b32b43d3d8"
    }
  }
]